MD3697789T2 - Derivați imidazol condensați substituiți cu grupări hidroxi terțiare ca inhibitori PI3K-GAMA - Google Patents

Derivați imidazol condensați substituiți cu grupări hidroxi terțiare ca inhibitori PI3K-GAMA

Info

Publication number
MD3697789T2
MD3697789T2 MDE20200857T MDE20200857T MD3697789T2 MD 3697789 T2 MD3697789 T2 MD 3697789T2 MD E20200857 T MDE20200857 T MD E20200857T MD E20200857 T MDE20200857 T MD E20200857T MD 3697789 T2 MD3697789 T2 MD 3697789T2
Authority
MD
Moldova
Prior art keywords
pi3k
hydroxy groups
imidazole derivatives
derivatives substituted
gamma inhibitors
Prior art date
Application number
MDE20200857T
Other languages
English (en)
Inventor
Brent Douty
Andrew W Buesking
David M Burns
Andrew P Combs
Nikoo Falahatpisheh
Ravi Kumar Jalluri
Daniel Levy
Padmaja Polam
Lixin Shao
Stacey Shepard
Artem Shvartsbart
Richard B Sparks
Eddy W Yue
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MD3697789T2 publication Critical patent/MD3697789T2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Această cerere de brevet se referă la compuşii cu Formula (I):sau la săruri acceptabile farmaceutic ale acestora, care sunt inhibitori de PI3K-γ care sunt utili pentru tratamentul tulburărilor cum ar fi bolile autoimune, cancerul, bolile cardiovasculare şi bolile neurodegenerative.
MDE20200857T 2017-10-18 2018-10-17 Derivați imidazol condensați substituiți cu grupări hidroxi terțiare ca inhibitori PI3K-GAMA MD3697789T2 (ro)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762574057P 2017-10-18 2017-10-18
US201762608897P 2017-12-21 2017-12-21
US201862727316P 2018-09-05 2018-09-05
PCT/US2018/056311 WO2019079469A1 (en) 2017-10-18 2018-10-17 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA

Publications (1)

Publication Number Publication Date
MD3697789T2 true MD3697789T2 (ro) 2022-02-28

Family

ID=64110207

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20200857T MD3697789T2 (ro) 2017-10-18 2018-10-17 Derivați imidazol condensați substituiți cu grupări hidroxi terțiare ca inhibitori PI3K-GAMA

Country Status (33)

Country Link
US (3) US10738057B2 (ro)
EP (2) EP4006034A1 (ro)
JP (2) JP7244504B2 (ro)
KR (1) KR20200089264A (ro)
CN (2) CN111542526B (ro)
AU (2) AU2018350980B2 (ro)
BR (1) BR112020007593A2 (ro)
CA (1) CA3084589A1 (ro)
CL (1) CL2020001047A1 (ro)
CR (2) CR20200214A (ro)
CY (1) CY1124814T1 (ro)
EC (1) ECSP20024651A (ro)
ES (1) ES2902390T3 (ro)
GE (1) GEP20237483B (ro)
HR (1) HRP20211827T1 (ro)
HU (1) HUE056615T2 (ro)
IL (3) IL295978B2 (ro)
JO (1) JOP20200086A1 (ro)
LT (1) LT3697789T (ro)
MA (1) MA50398B1 (ro)
MD (1) MD3697789T2 (ro)
MX (1) MX2020003862A (ro)
PE (1) PE20210169A1 (ro)
PH (1) PH12020550442A1 (ro)
PL (1) PL3697789T3 (ro)
PT (1) PT3697789T (ro)
RS (1) RS62818B1 (ro)
SG (1) SG11202003428VA (ro)
SI (1) SI3697789T1 (ro)
TW (2) TWI834560B (ro)
UA (1) UA128085C2 (ro)
WO (1) WO2019079469A1 (ro)
ZA (1) ZA202201220B (ro)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018350980B2 (en) 2017-10-18 2023-02-23 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
EP4151641A1 (en) 2017-12-19 2023-03-22 Turning Point Therapeutics, Inc. Macrocyclic compounds for treating cancer
HUE057970T2 (hu) * 2018-03-08 2022-06-28 Incyte Corp Aminopirazindiol-vegyületek mint PI3K-Y inhibitorok
GEP20237548B (en) 2018-07-05 2023-10-10 Incyte Corp Fused pyrazine derivatives as a2a /a2b inhibitors
LT3847175T (lt) * 2018-09-05 2024-03-25 Incyte Corporation Fosfoinozitido 3-kinazės (pi3k) inhibitoriaus kristalinės formos
CN115286521B (zh) * 2022-07-11 2023-11-03 上海医药集团(本溪)北方药业有限公司 一种盐酸左沙丁胺醇的合成方法

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4269846A (en) 1979-10-29 1981-05-26 Usv Pharmaceutical Corporation Heterocyclic compounds useful as anti-allergy agents
US5137876A (en) 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0011092D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
IL153231A0 (en) 2000-06-28 2003-07-06 Smithkline Beecham Plc Wet milling process
IL160915A0 (en) 2001-09-19 2004-08-31 Aventis Pharma Sa Indolizines inhibiting kinase proteins
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
MXPA04003954A (es) 2001-10-26 2004-11-29 Aventis Pharma Inc Bencimidazoles.
RU2337692C3 (ru) 2001-10-30 2020-11-09 Новартис Аг Производные стауроспорина в качестве ингибиторов активности рецепторной тирозинкиназы flt3
DE10207843A1 (de) 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) * 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
EP1599474B1 (en) 2003-03-04 2013-04-24 California Institute Of Technology Heterocyclic oligomeric compounds for DNA recognition
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2007501189A (ja) 2003-08-01 2007-01-25 ジェネラブス テクノロジーズ，インコーポレイテッド フラビウイルス科に対する二環式イミダゾール誘導体
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
UA83509C2 (en) * 2003-10-15 2008-07-25 Оси Фармасьютикалз, Инк. Imidazopyrazines as tyrosine kinase inhibitors
WO2005118580A2 (en) 2004-05-12 2005-12-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Tricyclic compounds as inhibitors of the hypoxic signaling pathway
ES2396135T3 (es) 2004-06-10 2013-02-19 Irm Llc Compuestos y composiciones como inhibidores de proteínas cinasas
EP1885352A2 (en) 2004-11-24 2008-02-13 Novartis AG Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
WO2007019417A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
TW200800213A (en) 2005-09-02 2008-01-01 Abbott Lab Novel imidazo based heterocycles
BRPI0713328A2 (pt) 2006-06-22 2012-10-30 Biovitrum Ab derivados de piridina e pirazina como inibidores de cinase mnk
CA2681813A1 (en) 2007-03-27 2009-01-08 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
EA020777B1 (ru) 2007-11-16 2015-01-30 Инсайт Корпорейшн 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus
JP2011507851A (ja) 2007-12-19 2011-03-10 ザ スクリプス リサーチ インスティチュート Ｒｈｏキナーゼインヒビターとしてのベンゾイミダゾールおよびアナログ
US8623347B2 (en) 2008-01-15 2014-01-07 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
US8329697B2 (en) 2008-02-26 2012-12-11 Merck Sharp & Dohme Corp. Imidizo[1,2-A]pyrazines useful as AHCY hydrolase inhibitors
TWI444382B (zh) 2008-03-11 2014-07-11 Incyte Corp 作為ｊａｋ抑制劑之氮雜環丁烷及環丁烷衍生物
AR071523A1 (es) 2008-04-30 2010-06-23 Merck Serono Sa Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento
WO2009158118A2 (en) 2008-05-30 2009-12-30 University Of Notre Dame Du Lac Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria
US8470819B2 (en) 2008-11-03 2013-06-25 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
WO2010061903A1 (ja) 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2010135014A1 (en) 2009-02-27 2010-11-25 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
CA2756759C (en) * 2009-04-16 2017-11-07 Joaquin Pastor Fernandez Imidazopyrazines for use as kinase inhibitors
ES2487542T3 (es) 2009-05-22 2014-08-21 Incyte Corporation Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus
KR101763656B1 (ko) 2009-06-29 2017-08-01 인사이트 홀딩스 코포레이션 Ｐｉ3ｋ 저해물질로서의 피리미디논
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
TW201130842A (en) 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
TWI766281B (zh) 2010-03-10 2022-06-01 美商英塞特控股公司 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物
JP2013523766A (ja) 2010-03-31 2013-06-17 グラクソ グループ リミテッド キナーゼ阻害剤としてのイミダゾリル‐イミダゾール
JP5816678B2 (ja) 2010-04-14 2015-11-18 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ＰＩ３Ｋδ阻害剤としての縮合誘導体
EP2575866A4 (en) 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc HCV NS5A INHIBITORS
EP2627650A2 (en) 2010-05-26 2013-08-21 Merck Sharp & Dohme Corp. N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
SG189396A1 (en) 2010-10-13 2013-05-31 Millennium Pharm Inc Heteroaryls and uses thereof
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
AR083933A1 (es) 2010-11-19 2013-04-10 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US8729102B2 (en) 2010-11-30 2014-05-20 Takeda Pharmaceutical Company Limited Bicyclic compound
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US8673905B2 (en) 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR20140093610A (ko) 2011-04-21 2014-07-28 재단법인 한국파스퇴르연구소 소염 화합물
EP2718279B1 (en) 2011-06-09 2016-08-10 Rhizen Pharmaceuticals SA Novel compounds as modulators of gpr-119
EA201490042A1 (ru) 2011-06-20 2014-10-30 Инсайт Корпорейшн Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
WO2013033569A1 (en) 2011-09-02 2013-03-07 Incyte Corporation Heterocyclylamines as pi3k inhibitors
US9260435B2 (en) 2012-01-10 2016-02-16 Bayer Pharma Aktiengesellschaft Substituted imidazopyrazines as Akt kinase inhibitors
US9212169B2 (en) 2012-03-01 2015-12-15 Hyogo College Of Medicine Benzimidazole derivative and use thereof
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
CN104334552B (zh) 2012-05-31 2016-08-31 住友化学株式会社 稠合杂环化合物
BR112015000675B1 (pt) 2012-07-13 2022-07-12 UCB Biopharma SRL Derivados de imidazopiridina como moduladores da atividade de tnf
CN107936039A (zh) 2012-11-01 2018-04-20 因赛特公司 作为jak抑制剂的三环稠合噻吩衍生物
TWI687220B (zh) 2013-03-01 2020-03-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
WO2014149207A2 (en) 2013-03-15 2014-09-25 Dow Agrosciences Llc Benzimidazole-based insecticidal compositions and related methods
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
EP2976077A4 (en) 2013-03-22 2016-11-30 Scripps Research Inst BENZIMIDAZOLES SUBSTITUTED AS MODULATORS OF A NOCICEPTIN RECEPTOR
WO2014182954A1 (en) 2013-05-08 2014-11-13 Colorado Seminary, Which Owns And Operates The University Of Denver Antibiotic and anti-parasitic agents that modulate class ii fructose 1,6-bisphosphate aldolase
PL3786162T3 (pl) 2013-05-17 2024-04-08 Incyte Holdings Corporation Pochodne bipirazolu jako inhibitory jak
CN105408325B (zh) 2013-07-17 2019-10-22 大塚制药株式会社 氰基三唑化合物
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106413716B (zh) 2014-04-08 2020-03-27 因赛特公司 通过jak和pi3k抑制剂组合治疗b细胞恶性肿瘤
EP2930048A1 (en) 2014-04-10 2015-10-14 Johnson Controls Automotive Electronics SAS Head up display projecting visual information onto a screen
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
CA2961525A1 (en) 2014-09-16 2016-03-24 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2016064957A1 (en) * 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors
WO2016064958A1 (en) * 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors
MA40933A (fr) 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
WO2016106624A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
US9968604B2 (en) 2015-04-16 2018-05-15 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
CN107849036A (zh) 2015-05-12 2018-03-27 卡利拉制药公司 二环化合物
AR106595A1 (es) 2015-11-06 2018-01-31 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
US20170190689A1 (en) 2016-01-05 2017-07-06 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
EP3505171A4 (en) 2016-08-26 2020-08-26 Mitsubishi Tanabe Pharma Corporation BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND
WO2018136754A1 (en) 2017-01-20 2018-07-26 Massachusetts Institute Of Technology Injectable polymer micro-depots for controlled local drug delivery
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
RS65492B1 (sr) 2017-07-24 2024-05-31 Novartis Ag Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
KR20200101330A (ko) 2017-10-18 2020-08-27 에피자임, 인코포레이티드 Ehmt2 저해제로서의 아민-치환된 헤테로사이클릭 화합물, 이의 염, 및 이들의 합성 방법
AU2018350980B2 (en) 2017-10-18 2023-02-23 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
EP4151641A1 (en) 2017-12-19 2023-03-22 Turning Point Therapeutics, Inc. Macrocyclic compounds for treating cancer
CR20210307A (es) 2017-12-21 2021-07-27 Boehringer Ingelheim Int NUEVAS PIRIDOPIRIMIDINONAS SUSTITUIDAS CON BENCILAMINO Y DERIVADOS COMO INHIBIDORES DE SOS1 (Divisional 2020-312)
UA127604C2 (uk) 2017-12-21 2023-11-01 Басф Се Пестицидні сполуки
LT3847175T (lt) 2018-09-05 2024-03-25 Incyte Corporation Fosfoinozitido 3-kinazės (pi3k) inhibitoriaus kristalinės formos

Also Published As

Publication number Publication date
GEP20237483B (en) 2023-03-27
US20200385392A1 (en) 2020-12-10
JP7244504B2 (ja) 2023-03-22
MA50398A (fr) 2021-05-05
IL273983B (en) 2022-10-01
IL273983B2 (en) 2023-02-01
ECSP20024651A (es) 2020-06-30
US11926630B2 (en) 2024-03-12
HRP20211827T1 (hr) 2022-03-18
SI3697789T1 (sl) 2022-04-29
IL295978B1 (en) 2023-09-01
IL295978B2 (en) 2024-01-01
IL273983A (en) 2020-05-31
PL3697789T3 (pl) 2022-02-21
HUE056615T2 (hu) 2022-02-28
CL2020001047A1 (es) 2020-08-28
EP4006034A1 (en) 2022-06-01
CN111542526B (zh) 2024-01-09
RS62818B1 (sr) 2022-02-28
LT3697789T (lt) 2021-12-10
KR20200089264A (ko) 2020-07-24
MA50398B1 (fr) 2021-10-29
PH12020550442A1 (en) 2021-05-31
ZA202201220B (en) 2023-03-29
TWI803525B (zh) 2023-06-01
CR20210442A (es) 2021-12-20
PT3697789T (pt) 2021-12-31
TWI834560B (zh) 2024-03-01
AU2023203088A1 (en) 2023-06-15
SG11202003428VA (en) 2020-05-28
AU2018350980A1 (en) 2020-04-30
US20220213107A1 (en) 2022-07-07
US10738057B2 (en) 2020-08-11
CY1124814T1 (el) 2022-11-25
CR20200214A (es) 2020-07-25
EP3697789A1 (en) 2020-08-26
IL295978A (en) 2022-10-01
US11225486B2 (en) 2022-01-18
CA3084589A1 (en) 2019-04-25
BR112020007593A2 (pt) 2020-09-24
AU2018350980B2 (en) 2023-02-23
JOP20200086A1 (ar) 2020-04-30
MX2020003862A (es) 2020-08-13
CN111542526A (zh) 2020-08-14
EP3697789B1 (en) 2021-09-29
WO2019079469A1 (en) 2019-04-25
US20190152975A1 (en) 2019-05-23
ES2902390T3 (es) 2022-03-28
TW201927788A (zh) 2019-07-16
UA128085C2 (uk) 2024-04-03
PE20210169A1 (es) 2021-01-29
TW202340200A (zh) 2023-10-16
JP2021500340A (ja) 2021-01-07
JP2023085290A (ja) 2023-06-20
CN118063470A (zh) 2024-05-24

Similar Documents

Publication Publication Date Title
MD3371190T2 (ro) Compuși heterociclici ca inhibitori PI3K-gamma
MD3436461T2 (ro) Compuși pirolotriazină ca inhibitori TAM
MD3697789T2 (ro) Derivați imidazol condensați substituiți cu grupări hidroxi terțiare ca inhibitori PI3K-GAMA
MD3762368T2 (ro) Compuși diol aminopirazină ca inhibitori ai PI3K-Y
EA202091267A1 (ru) 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
MD3368541T2 (ro) Compoziții și procedee de inhibare a activității arginazei
EA201890338A1 (ru) Оксадиазольные производные, пригодные в качестве ингибиторов hdac
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201691141A1 (ru) Соединения против ccr6
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
TN2018000372A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions.
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA201990418A1 (ru) Производные оксадиазолопиридина для применения в качестве ингибиторов грелин-о-ацилтрасферазы (goat)
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
MD3265459T2 (ro) Compuși amidici în calitate de agoniști ai receptorilor 5-HT4
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
EA202090414A1 (ru) Соединения и их применение
GEP20207130B (en) Imidazolone compounds as human neutrophil elastase inhibitors
EA201501123A8 (ru) Новые (циано-диметил-метил)-изоксазолы и -[1,3,4]тиадиазолы
EA202190271A1 (ru) Замещенные триазолохиноксалиновые производные
MD3303331T2 (ro) Modulatori alosterici pozitivi ai receptorilor muscarinici M1